Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dato-DXd with or without pembrolizumab in first-line advanced or metastatic PD-L1-high NSCLC
ISRCTN24189848Phase 3Active, not recruiting
- Sponsor
- Syneos Health
- Start
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Dato-DXd + pembrolizumab with Pembrolizumab alone (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Jan 2022; status: active, not recruiting.
02
Drugs
datopotamab deruxtecanpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ISRCTN24189848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN24189848.